In this study, we demonstrated that Torularhodin has an anti-obesity and anti-hepatic dyslipidemia effect through regulating the expression of the PPARα signaling pathway-related proteins to increase fat degradation and cholesterol execration accompanying reduced lipid absorption. This evidence concerns the gene PPARA and obesity due to melanocortin 4 receptor deficiency.